Abstract:Background: Remodeling of the extracellular matrix (ECM) is a hallmark of heart failure (HF). Our previous analysis of the secretome of murine cardiac fibroblasts returned ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5) as one of the most abundant proteases. ADAMTS5 cleaves chondroitin sulfate proteoglycans such as versican. The contribution of ADAMTS5 and its substrate versican to HF is unknown. Methods: Versican remodeling was assessed in mice lacking the catalytic domain of ADAMTS5 (Adamts5 ΔCat ). Proteomics was applied to study ECM remodeling in left ventricular samples from patients with HF, with a particular focus on the effects of common medications used for the treatment of HF. Results: Versican and versikine, an ADAMTS-specific versican cleavage product, accumulated in patients with ischemic HF. Versikine was also elevated in a porcine model of cardiac ischemia/reperfusion injury and in murine hearts after angiotensin II infusion. In Adamts5 ΔCat mice, angiotensin II infusion resulted in an aggravated versican build-up and hyaluronic acid disarrangement, accompanied by reduced levels of integrin β1, filamin A, and connexin 43. Echocardiographic assessment of Adamts5 ΔCat mice revealed a reduced ejection fraction and an impaired global longitudinal strain on angiotensin II infusion. Cardiac hypertrophy and collagen deposition were similar to littermate controls. In a proteomics analysis of a larger cohort of cardiac explants from patients with ischemic HF (n=65), the use of β-blockers was associated with a reduction in ECM deposition, with versican being among the most pronounced changes. Subsequent experiments in cardiac fibroblasts confirmed that β1-adrenergic receptor stimulation increased versican expression. Despite similar clinical characteristics, patients with HF treated with β-blockers had a distinct cardiac ECM profile. Conclusions: Our results in animal models and patients suggest that ADAMTS proteases are critical for versican degradation in the heart and that versican accumulation is associated with impaired cardiac function. A comprehensive characterization of the cardiac ECM in patients with ischemic HF revealed that β-blockers may have a previously unrecognized beneficial effect on cardiac chondroitin sulfate proteoglycan content.

Fibrosis uncovered: ADAMTS12 cuts to the core of extracellular matrix drama

ECM remodelling by ADAMTS12 in fibrosis

ADAMTS12 promotes fibrosis by restructuring extracellular matrix to enable activation of injury-responsive fibroblasts

ADAM15 in Fibroblasts: Improving the Matrix Remodeling by Blocking the Action of Transforming Growth Factor-β1

Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling

ADAMTS16 Activates Latent TGF-β, Accentuating Fibrosis and Dysfunction of the Pressure-Overloaded Heart.

New insights into fibrosis from the ECM degradation perspective: the macrophage-MMP-ECM interaction

Emerging roles for the ADAMTS-like family of matricellular proteins in cardiovascular disease through regulation of the extracellular microenvironment

Exploring Extracellular Matrix Crosslinking as a Therapeutic Approach to Fibrosis

Extracellular Matrix Metabolism and Fibrotic Disease

Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis

Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis

Secreted Protease ADAMTS18 in Development and Disease

Novel insights into the function and dynamics of extracellular matrix in liver fibrosis

ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis

Exuberant fibroblast activity compromises lung function via ADAMTS4 (vol 587, pg 466, 2020)

The role of metabolic reprogramming and de novo amino acid synthesis in collagen protein production by myofibroblasts: implications for organ fibrosis and cancer

Fibroblasts in fibrosis: novel roles and mediators

Fibroblast Yap/Taz Signaling in Extracellular Matrix Homeostasis and Tissue Fibrosis

Role of ADAMTS-5 in Aortic Dilatation and Extracellular Matrix Remodeling

ECM1 Attenuates Hepatic Fibrosis by Interfering with Mediators of Latent TGF-β1 Activation